results are within ±15 mg/dl of the reference glucose values at BG concentration <100 mg/dl and within ±15% at BG concentrations ≥100 mg/dl (for each individual test strip lot) and (2) at least 99% of the results of all 3 lots together are within zones A and B of the consensus error grid.
For BG values <100 mg/dl, GLUCOCARD ™ G+ system showed 96.4% to 100% of results within ±15 mg/dl and 80.4% to 89.3% within ±10 mg/dl. GlucoMen ® areo showed 94.6% to 100% within ±15 mg/dl and 82.1% to 85.7% within ±10 mg/dl. At BG concentrations ≥100 mg/dl, 93.8% to 96.5% of the values measured with GLUCOCARD ™ G+ system were within ±15% and 79.2% to 86.1% within ±10%. For GlucoMen ® areo, 95.8% to 98.6% were within ±15% and 84.7% to 89.6% within ±10% in these BG concentrations. Considering all BG concentrations, 95% to 96.5% of GLUCOCARD ™ G+ system results and 97% to 97.5% of GlucoMen ® areo results were within the limits. 100% of the values were within zones A and B of the consensus error grid for both systems. The relative bias according to Bland and Altman 3 ranged from −3.2% to −0.8% for GLUCOCARD ™ G+ and from +0.3% to +2.2% for GlucoMen ® areo.
In this study, the 2 investigated BGMSs were shown to fulfill system accuracy criteria of ISO 15197:2013 when evaluated against a hexokinase-based reference method. The newer system, GlucoMen ® areo, showed a superior level of accuracy. 
